The hearing health company continues to expect organic growth of 3–6%.
✦ Clinical Takeaway ✦
No actionable change — this is a corporate financial update with no clinical or practice implications.
✦ Why It Matters ✦
Demant's confidence in its growth trajectory signals continued investment capacity in hearing technology R&D and market expansion.
✦ Key Points ✦
- 01Demant maintains 2026 organic growth guidance of 3–6%.
- 02Management characterizes a lower-end outcome as 'less likely'.
- 03
